<DOC>
	<DOCNO>NCT00787410</DOCNO>
	<brief_summary>This study multicentre , open label , non-comparative , two stage phase II trial ass activity ZD1839 ( IRESSA ) patient malignant mesothelioma . Patients receive trial treatment first-line therapy , administer continuously daily completion six 4-week cycle treatment , disease progression , unacceptable toxicity withdrawal consent . Patients continue show evidence response , disease stabilization clinical benefit ZD1839 may continue receive therapy beyond completion trail .</brief_summary>
	<brief_title>An Open-label , Phase II Trial ZD1839 ( IRESSA ) Patients With Malignant Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologicallyconfirmed malignant mesothelioma ( base pleural biopsy ) ; eligibility first line therapy malignant mesothelioma Uni bi dimensionally measurable disease No prior radiotherapy within 3 week enrolment trial No significant comorbid disease Other malignancy , either coexist diagnose within last 5 year , exception basal cell carcinoma cervical cancer situ Brian metastasis leptomeningeal carcinomatosis Any unresolved chronic toxicity great CTC grade 2 previous anticancer therapy Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , St. John 's Wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>malignant mesothelioma</keyword>
	<keyword>IRESSA</keyword>
	<keyword>ZD1839</keyword>
</DOC>